High-dose glucose–insulin–potassium has hemodynamic benefits and can improve cardiac remodeling in acute myocardial infarction treated with primary percutaneous coronary intervention: From a randomized controlled study by Li, Yanhui et al.
Journal of Cardiovascular Disease Research Vol. 1 / No 3 104 Available Online: www.jcdronline.org
High-dose glucose–insulin–potassium has hemodynamic 
beneﬁ  ts and can improve cardiac remodeling in acute myocardial 
infarction treated with primary percutaneous coronary 
intervention: From a randomized controlled study
Yanhui Li, Lin Zhang, Lei Zhang, Haiyong Zhang, Nianzhong Zhang, Zhongsu Yang, 
Mingming Gao, Xinchun Yang, Liang Cui
Heart Center, Beijing Chaoyang Hospital and Institute of Cardiovascular Disease, Capital Medical 
University, Beijing - 100020, P. R. China.
Address for correspondence: Dr. Yanhui Li, Heart Center, First Hoapital of Tsinghua University, Tsinghua 
University Medical school. No. 6 Jiuxianqiao 1ST Ave, Beijing - 100016, P. R. China. 
E-mail: yanhui.li@jcdronline.org
ABSTRACT
Objective: To evaluate the effects of high-dose glucose–insulin–potassium (GIK) solution on hemodynamics 
and cardiac remodeling in patients with acute myocardial infarction (AMI) treated with primary percutaneous 
coronary intervention (PCI). Patients and Methods: We observed the changes in the hemodynamic parameters 
in 26 patients with AMI. All patients received primary PCI before entering the study. All patients in the study 
were randomized into the GIK group (n = 14) or the control group (n = 12). Patients in the GIK group received 
high-dose GIK solution (25% glucose, 80 mmol/L KCl and 50 IU/L insulin; 1.5 ml/kg/h) over 24 h. Patients in 
the control group received standard therapy. We monitored the hemodynamic parameters at baseline and after 
6 h, 12 h, 18 h and 24 h, respectively. Then, we followed-up the cardiac function with echocardiography after 
7 days, 1 month and 6 months. Results: The basic clinical data was similar between the groups. Primary PCI 
was performed successfully in 25 patients. The two groups were indistinguishable in all factors measured. GIK 
solution did not have a deleterious effect on the hemodynamic parameters. The pulmonary capillary wedge 
pressure increased during the ﬁ  rst 12-h period and then decreased smoothly (F = 3.75, P = 0.02). The trends 
were similar between the two groups. The system vascular resistance index (SVRI) and pulmonary vascular 
resistance index (PVRI) decreased during the ﬁ  rst 12 h in the GIK group but increased in the control group. The 
GIK solution signiﬁ  cantly inﬂ  uenced SVRI (F = 4.71, P = 0.02). GIK solution improved the cardiac function 
measured by stroke volume (F = 4.11, P = 0.03) and cardiac index (F = 4.40, P = 0.02). In the 6-month follow-up, 
GIK improved cardiac remodeling (left ventricular diastolic diameter: 49.2 ± 2.89 vs. 53.9 ± 2.48, P < 0.001; 
left ventricular systolic diameter: 32.9 ± 2.24 vs. 35.9 ± 2.78, P < 0.01). Conclusion: High-dose GIK solution 
had no adverse effects on the hemodynamics in AMI patients treated with primary PCI. It can improve cardiac 
function by lowering  SVRI. In the 6-month follow-up, it improved cardiac remodeling.
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INTRODUCTION
The concept that the metabolic cocktail, glucose–insulin–
potassium (GIK), may protect ischemic cardiomyocytes was 
ﬁ  rst popularized by Sodi-Pallares as a “polarizing agent” in 
1962.[1] Opie further proposed the rationale for the use of 
this metabolic therapy in 1970,[2] when he suggested two 
main mechanisms: the promotion of cardiac glycolysis and 
the diversion of free fatty acid (FFA) to adipocytes, with 
a resultant reduction in cardiac FFA metabolism.[3-9] In 
the “reperfusion therapy era,” the randomized controlled 
Estudios Cardiologicos Latinoamerica (ECLA) study 
suggested that only those patients who had received high-
dose GIK therapy had a statistical survival advantage over Li, et al.: High-dose GIK has beneﬁ  ts in AMI
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the control group.[10-13] In another study, Ceremuzynski et 
al. did not show any beneﬁ  cial effects of low-dose GIK 
therapy.[14] But, the acute hemodynamic effects and chronic 
cardiac function improvement of high-dose GIK therapy 
in acute myocardial infarction (AMI) patients were not 
well known, especially in patients treated with primary 
percutaneous coronary intervention (PCI).
The purpose of the present study is to analyze the 
hemodynamic changes during the first 24 h after 
intravenous administration of high-dose GIK solution 
in patients with a ST-segment elevated AMI who have 
received primary PCI.
PATIENTS AND METHODS
The study was conducted as a consecutive-designed, 
randomized and blank-controlled study in our center.
The inclusion criteria were suspected symptoms or signs 
with typical electrocardiographic changes, which is ST-
segment continuous elevation ≥1 mm in at least two 
adjacent leads or new LBBB(left bundle branch block), and 
time to be randomized ≤12 h from onset of symptoms.
The exclusion criteria were as follows:
(1)   Known renal impairment: the level of serum 
creatinine >2.0 mg/dl
(2)   Known hyperkalemia: the level of serum potassium 
>5.5 mmol/L
The purpose and details of the study were explained to all 
patients and written informed consent was obtained from 
all of them. The protocol was approved by the Ethical 
Committee of our hospital.
Hemodynamic measurements 
After admission, each subject had a chest X-ray and 
hemodynamic measurements were made under aseptic 
conditions in a special equipped room in the critical 
care unit. All patients underwent right-side heart 
catheterization at the bedside with a 4-lumen balloon-tipped 
thermodilution catheter (heparin-coated thermodilution 
catheter; 7Fr 4-lumin 110 cm; arrow AH-05000-H, 
Teleﬂ  ex Incorporated, Limerick, PA, USA). The pressure 
was recorded by means of strain gauge transducers. The 
reference level was 5 cm below the sternum in the supine 
position. Cardiac output (CO) was determined with the 
thermodilution method. Each recorded value was based 
on a mean of at least two accepted measurements within 
10% variation. All measurements and pressure curves 
were recorded on paper and saved for later analyses. After 
insertion of the catheters, the patients rested for 10 min 
and then a control reading, including CO, mean right 
atrial pressure (RAP), pulmonary artery pressure (PAP) 
and mean pulmonary capillary wedge pressure (PCWP), 
was performed. System blood pressure (BP) was obtained 
using a cuff-sphygmomanometer. Pressure monitoring 
and hemodynamic parameter calculating were completed 
using the Eagle 4000 patient monitor instruction (GE 
Medical Systems Company, Marquette, WI, USA). The 
following indices were derived from the measurement 
obtained. Cardiac index (CI) = CO/body surface area 
(BSA), stroke volume (SV) = CO/heart rate (HR) *1000, 
mean artery pressure (MAP) = (SBP-DBP)/3 + DBP, 
system vascular resistance (SVR) = (MAP-RAP) * 79.92/
CO, system vascular resistance index (SVRI) = SVR/BSA, 
pulmonary vascular resistance (PVR) = (PAP-PCWP) * 
79.92/CO, pulmonary vascular resistance index (PVRI) = 
PVR/BSA, left ventricular stroke work index (LVSWI) = 
SV * (MAP-PCWP) * 0.0136/BSA, right ventricular stroke 
work index (RVSWI) = SV * (PAM-RAP) * 0.0136/BSA. 
Hemodynamic measurements were repeated at baseline, 6 
h, 12 h, 18 h and 24 h. The BSA was calculated based on the 
formula, BSA = height (m)0.725 * weight (kg)0.425 * 0.007184.
DRUG ADMINISTRATION
Preparation of high-dose GIK solution (glucose 25%, 
insulin 50 IU/L and KCl 80 mmol/L): 10% glucose 300 ml 
+ 50% glucose 200 ml + 15% KCl 20 ml + insulin 26 IU.
If the patient was randomized into the GIK group, GIK 
solution was given by an infusion of 1.5 ml/kg/h over 24 h 
after baseline hemodynamic measurement obtained. If the 
patient was randomized into the control group, standard 
therapy was given.
Correction of the speed of GIK infusion
The initial dose of GIK is standard. The speed of the GIK 
infusion was not adjusted before the serum concentration 
of glucose and potassium were obtained. When the serum 
glucose concentration was between 250 mg/dl and 350 
mg/dl before or during the intravenous administration, 
it was considered to be down-regulated and then the 
patients were administered extra insulin by means of 
intravenous or hypodermal routes rather than adjusting 
the GIK infusion. However, in the presence of following 
conditions: pulmonary edema, serum glucose > 350 mg/
dl in the 6th hour after GIK infusion or serum potassium 
> 5.5 mmol/L, GIK infusion speed was adjusted.Li, et al.: High-dose GIK has beneﬁ  ts in AMI
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Biochemical analysis
Laboratory analyses including serum concentration of 
glucose and potassium before randomization (baseline), 6 h 
and 24 h after randomization and the levels of serum cTnI, 
were performed. The serum concentrations of glucose 
and potassium were measured with a fully automated 
biochemical instrument. The levels of serum cTnI were 
analyzed using the OPUS instrument.
Statistical methods
All continuous data were expressed as mean ± standard 
deviation. Repeated-measures ANOVA was used to 
assess the effects of intervention factor (GIK infusion) 
on hemodynamics. Time was as repeated-measurement 
factors. The type I error was kept at 5% (α = 0.05). A 
P value of <0.05 was considered statistically signiﬁ  cant.
RESULTS
Patient characteristics [Table 1] 
Primary PCI was performed in 25 patients. One additional 
patient did not receive myocardial reperfusion therapy.
Clinical ﬁ  ndings
The tendency of HR and BP is shown in Table 2. There 
are no signiﬁ  cant differences between the two groups 
[Table 2]. Also, the high-dose GIK infusion has no 
signiﬁ  cant effect on the HR and BP (HR: F = 0.46, P = 
0.67; MAP: F = 0.93, P = 0.43). The serum concentrations 
of glucose and potassium increased significantly due 
to GIK infusion [Tables 3 and 4]. Generally, the serum 
glucose concentration in patients with diabetes mellitus 
Table 1: Patient characteristics




M 75 1 Infra-posterior, 
RV
RCA 2 35.7
M 44 2 Extensive 
anterior
LAD 1 29.9
M 77 1 Anterior LAD 2 0.133
M 70 1 Extensive 
anterior
LAD 2 >50
F 70 1 Anterior LAD 3 13
M 71 2 Extensive 
anterior
LAD 2 >50
M 68 2 Inferior, RV RCA 3 0.601
M 80 1 Inferior, RV RCA 3+ LM >50
M 58 2 Infra-posterior-
lateral
LCX 3 0.424
F 70 2 Extensive 
anterior
LAD 3 >50
F 64 1 Inferior RCA 1 9.07
F 64 2 Inferior, RV RCA 2 3.63
M 64 2 Inferior RCA 3+ LM 21.2
F 64 2 Infra-posterior RCA 3 >50
M 50 1 Infra-posterior-
lateral
LCX 2 7.07
F 67 2 Anterior LAD 3 14.1
M 67 1 Infra-posterior, 
RV
RCA 3 28.5
M 59 2 Infra-posterior RCA 3 >50
F 68 2 Inferior, RV RCA 3+ LM >50
M 77 1 Infra-posterior RCA 2 6.28
F 63 1 Anterior LAD 3+ LM >50
M 66 1 Anterior LAD 2 7.68
F 68 1 Inferior, RV RCA 2 >50
M 61 2 Infra-posterior-
lateral
LCX 3 11.7
F 71 1 Inferior, RV RCA 3+LM 26.4
M 40 1 Anterior LAD 1 >50
M, male; F, female; Group 1, GIK group; Group 2, control group; IRA, infarction-
related vessel; LM, left main; RCA, right coronary artery; LAD, left anterior 
descending; LCX, left circumﬂ  ex
Table 3: Blood glucose and serum potassium levels before and after GIK infusion
GIK group (n = 14) Control group (n = 12)
Baseline 12 h 24 h Baseline 12 h 24 h
cTnI (ng/ml) 25 ± 21 29 ± 21
Serum glucose (mg/dl)   157 ± 37 2  48 ± 99** 170 ± 95 22  2 ± 10  3* 188 ± 77 148 ± 57
Serum potassium (mmol/L) 3.9 ± 0.6 4.2 ± 0.7 4.6 ± 0.6 4.3 ± 0.5 4.2 ± 0.2 4.1 ± 0.3#
*P <0.05, **P <0.05 vs. GIK baseline; #P <0.05 vs. GIK 24 h
Table 2: The HR and BP at baseline, 6 h, 12 h, 18 h and 24 h in the two groups
GIK group (n = 14) Control group (n = 12)
Baseline 6 h 12 h 18 h 24 h Baseline 6 h 12 h 18 h 24 h
HR (bpm) 71 ± 14 71 ± 13 73 ± 15 72 ± 13 74 ± 11 71 ± 9 70 ± 9 68 ± 10 70 ± 9 72 ± 10
SBP (mmHg) 126 ± 16 125 ± 15 122 ± 24 118 ± 21 116 ± 12 118 ± 20 118 ± 16 123 ± 17 121 ± 15 120 ± 14
DBP (mmHg) 73 ± 7 71 ± 5 69 ± 7 72 ± 8 69 ± 7 70 ± 12 71 ± 9 71 ± 8 70 ± 10 69 ± 8
MAP (mmHg) 91 ± 7 89 ± 7 86 ± 11 87 ± 12 85 ± 6 86 ± 14 87 ± 11 88 ± 10 87 ± 11 86 ± 9Li, et al.: High-dose GIK has beneﬁ  ts in AMI
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(DM) was easy to be increased, yet it could be controlled 
to a satisfactory level with the adjustment of insulin 
administration. Although the potassium level increased, 
it was still in the normal range (<5.0 mmol/L). The GIK 
was never stopped or decelerated because of the progress 
of pulmonary edema. All the patients recovered and 
were discharged. During the hospitalization period, no 
malignant arrhythmia, reinfarction, heart failure, recurrent 
ischemia, hypoglycemia, cardiogenic shock or cardiac arrest 
occurred. Among the subjects, selected CABG (coronary 
artery bypass graft) was performed in three cases during 
the hospitalization period. Two patients in the GIK group 
experienced diuresis, about 4000–5000 ml/d. They were 
given proper ﬂ  uid for the maintenance of blood volume 
and electrolytes.
Acute hemodynamic effects
Among the 26 subjects, the Swan-Ganz catheter could be 
introduced into the pulmonary artery under pressure wave 
form monitoring at the bedside in 25 patients. In other 1 
patient, it’s failed under pressure wave form monitoring 
at the bedside, then successful with underlying X-ray in 
catheter lab. Pressure curves and thermodilution curves of 
good quality were registered in all patients during the entire 
period. The hemodynamic data are summarized in Table 5 
and Table 6. Soon after AMI, RAP increased slightly and 
then decreased gradually 12 h later (F = 2.2, P = 0.12). But, 
there were no signiﬁ  cant differences on the RAP between 
the GIK and the control groups (F = 0.06, P = 0.81). High-
dose GIK infusion had no signiﬁ  cant effect on the RAP (F 
= 0.15, P = 0.87). Similar to RAP, the PCWP also increased 
soon after AMI, then decreased 6 h later (F = 3.75, P = 
0.02). However, compared with the control, high-dose GIK 
infusion decreased PCWP soon after AMI. In the control 
group, the SVRI increased from 2706 ± 817 to 2952 ± 392 
after 12 h. But, it decreased from 2859 ± 531 to 2322 ± 436 
in the GIK group. The SVRI decreased gradually after 24 h 
in the two groups. High-dose GIK infusion had a signiﬁ  cant 
effect on the SVRI (F = 4.71, P = 0.02). The PVRI in the 
control group increased slightly at an earlier time and that 
of the GIK group presented a decreasing trend. There was 
no signiﬁ  cant effect of different times on the PVRI (F = 
0.19, P = 0.81). High-dose GIK infusion had no statistically 
signiﬁ  cant effect on the PVRI (F = 1.57, P = 0.22). The 
LVSWI increased gradually from 35 to 39 within 24 h after 
AMI (F = 1.91, P = 0.17). High-dose GIK infusion increased 
the LVSWI slightly, without any statistical signiﬁ  cance (F 
= 1.55, P = 0.23). The changes of RVSWI have the same 
tendency as LVSWI. SV showed an increasing trend from 
60.2 ± 16.5 ml to 68.9 ± 23.6 ml in the GIK group, yet that 
in the control showed a decreasing trend from 60.0 ± 17.7 
ml to 54.8 ± 11.0 ml at ﬁ  rst and then increased gradually 24 h 
later. High-dose GIK infusion increased the SV signiﬁ  cantly 
(F = 4.11, P = 0.03). Similar to SV, CI showed an increasing 
trend from 2.4 ± 0.5 to 2.8 ± 0.8 in the GIK group, yet that 
of the control presented a decreasing trend from 2.5 ± 0.6 
to 2.2 ± 0.4 within 12 h after AMI. High-dose GIK infusion 
improved the CI signiﬁ  cantly (F = 4.39, P = 0.02). There 
were no signiﬁ  cant differences in SV and CI between the 
GIK group and the control 24 h later.
Improvement of cardiac remodeling
After the treatment, during the acute period, all patients 
received standard therapy. A 6-month follow-up was 
performed. We assessed cardiac function and cardiac 
remodeling by echocardiography after 7 days, 1 month 
and 6 months. We observed that left ventricular diastolic 
diameter (LVDD) and left ventricular systolic diameter 
(LVSD) decreased from 7 days to 6 months in all patients. 
There were signiﬁ  cant differences in LVSD between the 
Table 4: Statistical results of serum glucose and 
potassium
Serum potassium Serum glucose
Effects F-value P value F-value P value
Time 2.818 0.073 6.170 0.008
Time*group 7.173 0.002 7.178 0.004
Group 0.026 0.873 0.035 0.854
Table 5: Hemodynamic data at different times between the two groups
GIK group (n = 14) Control group (n = 12)
Baseline 6 h 12 h 18 h 24 h Baseline 6 h 12 h 18 h 24 h
RAP 7.9   ± 4.5 8.3 ± 3.5 8.3 ± 3.5 7.6 ± 4.3 6.3 ± 4.0 6.9 ± 5.4 8.4 ± 4.6 7.9 ± 3.9 7.1 ± 2.0 6.3 ± 2.3
PCWP 12.3 ± 2.8 15.0 ± 4.8 12.8 ± 4.7 10.3 ± 6.2 9.8 ± 4.6 12.2 ± 4.8 13.2 ± 4.8 11.8 ± 3.6 12.5 ± 5.3 10.4 ± 5.3
SVRI 2859 ± 531    2322 ±   436 2308 ± 315 2706 ± 817 2952 ± 392*** 2494 ± 666
PVRI 277 ± 12  5 245 ± 98 215 ± 104 206 ± 89 259 ± 112 250 ± 95
LVSWI 35.6 ± 10.1 39.3 ± 13.5 38.7 ± 11.0 35.4 ± 12.1 34.0 ± 8.4 39.0 ± 9.6
RVSWI 5.6 ± 2.1 6.3 ± 2.3       5.7 ± 2.7 5.9 ± 4.0 5.0 ± 2.6 6.4 ± 3.3
SV 60.2 ± 16.5 68.9 ± 23.6 68.0 ± 21.9 60.0 ± 17.2 54.8 ± 11.0 63.7 ± 14.4
CI 2.4 ± 0.5 2.8 ± 0.8 2.7 ± 0.4 2.5 ± 0.6 2.2 ± 0.4 2.7 ± 0.6
***P <0.001 vs. GIK 12 hLi, et al.: High-dose GIK has beneﬁ  ts in AMI
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groups after the 6-month treatment. There were signiﬁ  cant 
differences in LVDD between the groups after the 1- and 
6-month treatment [Figures 1–3].
Adverse effects
Among the 26 subjects, two cases demonstrated 
hyperglycemia, although the hyperglycemia was corrected 
after hypodermal insulin administration and deceleration 
of GIK. No hyperkalemia was recorded. No patients in 
the GIK group manifested acute heart failure during the 
high-dose GIK infusion. The high-dose GIK infusion in 
acute MI patients is safe.
DISCUSSION
Our study has clearly shown that early after AMI, high-
dose GIK infusion improves cardiac function, as judged 
by hemodynamic measurements. Previous studies have 
shown the potential beneﬁ  cial effects of GIK on the 
reduction of infarct size, improvement in global ejection 
fraction in infarcted zone, lower pulmonary pressures 
and decrease in diastolic and systolic volumes.[15] The 
clinical beneﬁ  cial effects of high-dose GIK infusion 
and its mechanism are not, however, fully understood. 
Our previous study had shown that high-dose GIK can 
decrease the cardiomyocyte apoptosis in AMI patients 
with reperfusion therapy.[16] With high-dose GIK infusion, 
CI was increased and SV was improved without an 
increase in HR in our study. This suggests that GIK 
infusion can improve cardiac function in AMI patients 
at an early phase,[3,4,6,17,18] and that increase in the reﬂ  ex 
HR is not the mechanism. Our results showed that SVRI 
increased early after AMI. However, SVRI decreased 
signiﬁ  cantly in patients treated with high-dose GIK and 
increase in LVSWI did not reach statistical signiﬁ  cance. 
This indicates that SVRI lowering may play a key role 
in the mechanism. Because LVSWI increased slightly 
(difference not signiﬁ  cant), GIK solution can protect 
cardiomyocytes to some degree, although a large-scale 
international randomized trial, the CREATE-ECLA 
Figure 1: The changes of left ventricular diastolic diameter from day 
7 to 6 months between the glucose–insulin–potassium group and the 
control group **P<0.01 vs. GIK, ***P<0.001 vs. GIK
Figure 2: The changes of left ventricular systolic diameter from day 
7 to 6 months between the glucose–insulin–potassium group and the 
control group **P<0.01 vs. GIK
Figure 3: The changes of LVEF from day 7 to 6 months between the 
glucose–insulin–potassium group and the control group
trial,[19] indicated that high-dose GIK infusion had a 
neutral effect on mortality, cardiac arrest and cardiogenic 
shock in patients with acute STEMI during a 30-day 
follow-up. In the CREATE-ECLA trial, not all patients 
received primary PCI. And, data from the CREATE 
Table 6: Results of statistical analysis on hemodynamics
Time Time*group Group
F-value P value F-value P value F-value P value
RAP 2.197 0.120 0.154 0.873 0.062 0.807
PAWP 3.754 0.019 1.042 0.378 0.000 0.986
SVRI 4.522 0.020 4.706 0.017 1.182 0.291
PVRI 0.186 0.814 1.574 0.222 0.071 0.793
LVSWI 1.907 0.168 1.545 0.229 0.156 0.698
RVSWI 0.213 0.774 1.401 0.259 0.008 0.931
SV 3.076 0.061 4.108 0.027 0.785 0.307
CI 3.293 0.051 4.393 0.022 0.766 0.392Li, et al.: High-dose GIK has beneﬁ  ts in AMI
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trial is not similar to that from the ECLA trial. In our 
clinical practice, we found that high-dose GIK infusion 
could improve the clinical conditions in patients with 
cardiogenic shock due to AMI.
Also, we found that LVDD, LVSD and LVEF (left 
ventricular ejection fraction) improved after the 6-month 
standard therapy in all patients. Interesting, this was more 
signiﬁ  cant in the GIK group, suggesting that GIK could 
improve cardiac remodeling in AMI patients receiving 
primary PCI. But, the mechanism is not well known. Some 
mechanisms have been proposed for the association of 
GIK solution therapy with improved cardiac remodeling, 
including decreasing cardiomyocyte apoptosis, improving 
myocardial perfusion, improving myocardial metabolism, 
lowering SVRI and so on.
In conclusion, the preliminary observation suggests that 
high-dose GIK infusion results in improved cardiac 
function in the “myocardial reperfusion era” and SVR 
lowering could play some role in this mechanism.
LIMITATION
As the sample size is small in the study, it could potentially 
bias the results of the evaluation. If the sample size is 
large enough, increase in the LVSWI could reach statistical 
signiﬁ  cance. If this were the case, high-dose GIK infusion 
could improve myocardial contractility in some way.
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